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Abstract
Background: Excessive consumption of alcohol contributes to alcoholic liver disease. Fatty liver is the early stage
of alcohol-related liver disease. The aim of this study was to search for specific serological biomarkers of alcoholic
fatty liver (AFL) compared to healthy controls, non-alcoholic fatty liver (NAFL) and liver fibrosis in a rodent model.
Methods: Serum samples derived from animals with AFL, NAFL, or liver fibrosis were characterized and compared
using two-dimensional differential gel electrophoresis. A matrix-assisted laser desorption ionization-time of flight
tandem mass spectrometer in conjunction with mascot software was used for protein identification. Subsequently,
Western blotting and flexible multi-analyte profiling were used to measure the expressions of the putative
biomarkers present in the serum of animals and clinical patients.
Results: Eight differential putative biomarkers were identified, and the two most differentiated proteins, including
upregulated C-reactive protein (CRP) and downregulated haptoglobin (Hp), were further investigated. Western
blotting validated that CRP was dramatically higher in the serum of AFL compared to healthy controls and other
animals with liver disease of NAFL or liver fibrosis (p < 0.05). Moreover, we found that CRP and Hp were both
lower in liver fibrosis of TAA-induced rats and clinical hepatitis C virus-infected patients.
Conclusion: The results suggest that increased levels of CRP are an early sign of AFL in rats. The abnormally
elevated CRP induced by ethanol can be used as a biomarker to distinguish AFL from normal or otherwise
diseased livers.
Keywords: alcoholic fatty liver, biomarker, C - reactive protein, haptoglobin, two-dimensional differential gel
electrophoresis
Background
Excessive alcohol consumption affects lipid metabolism
in the liver [1,2], contributing to the development of
alcohol-related liver diseases. There are three main types
of alcohol-related liver disease, these are: alcoholic fatty
liver (AFL), alcoholic hepatitis, and alcoholic cirrhosis.
AFL is the early stage of alcohol-related liver diseases.
Therefore, identifying putative serum biomarkers of AFL
for early and accurate diagnostic methods is vital.
Histological assessment of liver biopsy specimens
remains the gold standard for determining alcohol-
related liver disease. However, the methodology of histo-
logical assessments needs to overcome several draw-
backs such as its invasive character and sampling error
[3]. Moreover, it has difficulty in distinguishing AFL
from non-alcoholic fatty liver solely through a histologi-
cal assessment. On the other hand, predicting ethanol-
induced oxidative stress and tissue injury in the liver
require particularly sensitive markers [4]. A previous
study suggested that glutamyl-transpeptidase (GGT) and
alanine aminotransferase (ALT) are biomarkers for diag-
nosing alcoholic liver disease [5]. Several reports pro-
posed that serum C-reactive protein (CRP), tissue
polypeptide-specific antigen (TPS), and interleukin-6 are
noninvasive biomarkers of alcoholic hepatitis [6-10].
Nevertheless, a reliable biomarker to predict the early
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any medium, provided the original work is properly cited.stage of alcoholic hepatitis, i.e., AFL, and to distinguish
AFL from other types of liver disease is needed.
A proteomics strategy based on two-dimensional differ-
ential gel electrophoresis (2D-DIGE) [11] allows for the
simultaneous resolution of thousands of proteins from
samples with high precision and replication. 2D-DIGE
was used to screen and determine putative biomarkers of
many diseases [12-15]. Those protein samples of interest
displayed on 2D-DIGE can be extracted and acquired
from gels for identification and further investigation. In
total, we discovered eight differential proteins associated
with AFL using 2D-DIGE, including the most differen-
tiated proteins: CRP and haptoglobin (Hp).
This study revealed that CRP is a novel early biomarker
of alcohol-induced fatty liver, and that CRP and Hp were
both particularly decreased with liver fibrosis. In conclu-
sion, we present CRP as a surveillance marker of alcohol-
induced fatty liver in a rodent model, which may help
diagnose early alcohol-induced pathophysiological altera-
tions in clinical practice.
Materials and methods
Animal model and sample preparation
Animal experimentation was performed according to
approved procedures of the Institute of Nuclear Energy
Research, Atomic Energy Council, Taoyuan, Taiwan
(approval no.: 98053). Wistar rats were used to generate
animals with AFL, non-AFL (NAFL), and liver fibrosis.
AFL rats (n = 6) were orally fed 5 ml of a 36% alcohol
solution for 4 weeks (6 g/kg/day) [16]. For rats with
NAFL, animals were given food containing 60% fructose
(n = 4) or 45% fat (n = 6) for 12 weeks. The liver-fibrosis
rats (n = 6) were fed 0.04% thioacetamide (TAA)-contain-
ing drinking water for 12 weeks. Control animals were fed
normal diets with no additives in their food (n = 7). Sera
and liver tissues were collected for further investigation.
Clinical serum collection
The sera of healthy volunteers (n = 16), patients with non-
alcoholic steatohepatitis (n = 19) and patients with hepatitis
C virus (HCV)-infected liver fibrosis (n = 17) were
obtained from Cheng Hsin General Hospital in Taiwan
(approval no. 97016). A liver biopsy and subsequent histo-
logical examination were used to assess the stage of liver
fibrosis according to the Metavir classification, and also to
determine the fatty change and modified HAI grade. A
liver biopsy was not performed in healthy controls due to
ethical issues.
2D-DIGE
Each 50 μg of protein from a normal control or AFL rat
was labeled with 400 pmol of Cy3 or Cy5 and the inter-
nal pooled standard (100 μg) was labeled with 800 pmol
of Cy2 for 30 min. The three labeled samples were
pooled together for analysis. IPG strips (18 cm) at pH
4~7 for the first-dimension IEF (Ettan IPGphor System,
GE Healthcare) and 12.5% polyacrylamide gels for the
second dimension were used to separate serum proteins.
The Cy2, Cy3, and Cy5-labeled images were acquired on
a Typhoon TRIO Variable Mode Imager (GE Health-
care) using 488-, 532-, and 633-nm lasers with respec-
tive emission filters of 520, 532, and 670 nm. Images
were analyzed using DeCyder 6.5 software (GE Health-
care) to select the differential proteins. Protein spots of
interest were selected according to an independent Stu-
dent’s t-test with a significant value of < 0.05.
Protein identification
In-gel digestion and MALDI-TOF MS analysis were per-
formed as previously described [13].
Western blotting
Each serum sample was diluted 1: 1 with a sodium dode-
cylsulfate (SDS) buffer containing 50 mM of Tris-Cl, 8 M
urea, 30% glycerol, 2% SDS, 20 mM of dithiothreitol, and
0.1% bromophenol blue. A 4%~12% SDS- polyacrylamide
gel electrophoresis (PAGE) (Invitrogen) was performed to
separate the proteins. The iblot (Invitrogen) was used to
transfer proteins to a polyvinylidene difluoride (PVDF)
membrane. After using 0.5% milk to blot the PVDF mem-
brane for 30 min, CRP and Hp were detected by a mouse
anti-CRP immunoglobulin G (IgG) (Affinity BioReagents)
and a mouse anti- Hp IgG (Sigma) for at least 1 h respec-
tively. The second antibody conjugated with horseradish
peroxidase (HRP) was incubated for 1 h at room tempera-
ture. The membranes were washed three times in phos-
phate-buffered saline (PBS; 10 mM sodium phosphate
(pH7.4) and 0.9% NaCl) between adding antibodies. The
Imaging System (Gel Doc XR System, Bio-Rad) was used
to acquire images depending on a moderate exploration
time and to semi-quantify protein expressions.
Measurement of CRP and Hp concentration
Flexible multi-analyte profiling (xMAP) was performed
to measure serum concentrations of CRP and Hp in
clinical samples using the commercial Bio-Plex Pro
Human Acute Phase 4-Plex Panel (Bio-Rad). The mea-
surment procedure followed instructions in the manual.
Statistical analysis
The statistical software, SPSS, was used to calculate the
significance according to Student’s t-test. Significance (p
value) was accepted as < 0.05.
Results
Animal models
Each experimental animal bearing a specific liver disease,
namely: AFL, NAFL and, liver fibrosis was analyzed and
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animal models, several indicators in the serum including
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), total bilirubin (TBIL), total cholesterol
(TCHO) and triglyceride (TG) were measured and com-
pared (Table 1). Levels of AST, ALT, and TBIL increased
in LF rats [199 ± 37 U/L (p < 0.01), 74.4 ± 19 U/L (p <
0.01), and 0.84 ± 0.10 mg/dl (p < 0.05), respectively] com-
pared to those in normal controls (AST 154 ± 25 U/L;
ALT 56 ± 15 U/L; and TBIL 0.70 ± 0.06 mg/dl), indicat-
ing that the liver function of LF rats was impaired. How-
ever, no significant changes in these three serum
indicators in AFL and NAFL were observed. Other indi-
cators, TCHO and TG, were measured to observe lipid
accumulation in the liver. An increased TG level was
observed only in the group of rats fed the high concen-
tration of fructose (91 ± 14 mg/dl, p < 0.05) compared to
other rats fed different diets, but the TCHO level
remained unchanged. These results show that AST, ALT,
and TBIL increased in the serum of LF rats, and TG
increased in rats that were fed a high level fructose.
Therefore, these existing serum indicators so far could
not be used to distinguish AFL from the normal controls,
which means that finding differential biomarkers of AFL
is vital.
On the other hand, we observed that there was no sig-
nificant difference in the morphology of livers among
normal, AFL and, NAFL rats except for rats with liver
fibrosis showing excess scars (Figure 1). To more-deeply
assess our established rodent models using histological
examinations, the results showed that livers of rats with
AFL appeared to specifically be filled with macrovesicu-
lar fat within hepatocytes compared to normal controls
according to histological staining with hematoxylin and
eosin (H&E) (Figure 1), demonstrating that ethanol
treatment induced lipid accumulation in the liver.
Furthermore, signs of focal necroinflammation were
absent from the liver tissues of rats with AFL (Figure 1).
Discovery of AFL biomarkers using 2D-DIGE
In order to explore the signature molecular biomarkers
of AFL, a proteomic methodology, 2D-DIGE, described
above “Materials and methods” was performed to ana-
lyze individual serum from two normal controls or two
AFL rats shown on Figure 2A to search for putative bio-
markers of AFL. In the 2D-DIGE analysis, Cy3 and Cy5
were used to individually label serum samples from nor-
mal controls and AFL rats. For sample normalization,
Cy2 was used to label the internal standard including
50% of normal and 50% of AFL rats. The protein image
was presented as shown in Figure 2B. Normal control
sera were labeled with Cy3 and appeared colored green
in the gel. Samples derived from rats with AFL were
p r e - l a b e l e dw i t hC y 5a n ds h o w e da sar e dc o l o ri nt h e
gel. Eight differential proteins including CRP, Hp, afa-
min, alpha-fetoprotein (AFP), inter-alpha-inhibitor H4
heavy chain (ITIH4), serine protease inhibitor Kazal-
type 5 (SPINK5), heak shock protein 75 kDa (HSP75),
and vitamin D binding protein prepeptide (VDBP) were
acquired according to the statistical analysis with signifi-
cant p values (t-test, p < 0.05), and an intensity change
ratio of > 1.2-fold calculated with DeCyder software.
The location of each protein is shown in Figure 2C.
When using a stereopicture and detailed gel images to
present the protein expressions of differential biomar-
kers (Figure 3), CRP, AFP and afamin were increased
higher in the serum of AFL rats, and Hp, ITIH4,
SPINK5, HSP75, and VDBP were conversely lower. In
particular, Hp, ITIH4 and SPINK5 had a series of spots
nearby, but the protein expressional trends were still the
same. We speculated that post-translational modification
would not affect or influence the protein expression.
Essentially, we identified protein spots by comparing the
mass spectrum obtained from MALDI-TOF MS coupled
with the NCBI database. The proteins identified are
shown in Table 2. According to the set calculation in
the DeCyder software, the upregulation (+) is presented
Table 1 Levels of some clinical serum indicators in the animals
Indicators Normal
(n =7 )
AFL
(n =6 )
HF-NAFL (n = 4) HL-NAFL (n =6 ) L F
§
(n =5 )
BW (g) 270 ± 5
¶/457 ± 14
§ 275 ± 3
¶ 418 ± 28
§ 565 ± 29
§,*N D
AST (U/L) 154 ± 25 148 ± 34
c 164 ± 31 181 ± 63 199 ± 37*
ALT (U/L) 56 ± 15 41 ± 13
c 48 ± 17 57 ± 22 74 ± 19*
TBIL
(mg/dl)
0.70 ± 0.06 0.62 ± 0.09
a, b, c 0.78 ± 0.04 0.75 ± 0.05 0.84 ± 0.10*
TG
(mg/dl)
51 ± 16 58 ± 10
a 91 ± 14** 56 ± 11 48 ± 14
TCHO
(mg/dl)
61 ± 10 68 ± 8 72 ± 10 71 ± 12 61 ± 17
BW, body weight; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirulin; TG, triglyceride; TCHO, total cholesterol; AFL, alcoholic fatty
liver; HF-NAFL, high fructose-induced non-alcoholic fatty liver; HL-NAFL, high lipid-induced non-alcoholic fatty liver; LF, liver fibrosis. Indicators for predicting liver
function include GOT, GPT, and bilirubin and for predicting fat cells include triglyceride and cholesterol. Rats were treated before the age of 6 weeksa n d
sacrificed by the ages of
¶10 and
§18 weeks. ND, Non-detection. The p value was calculated according to Student’s t-test. * p < 0.05 and **p < 0.01 as compared
to normal controls. A significant change (p < 0.05) was also determined for AFL rats compared to
aHF-NAFL,
bHL-NAFL, and
cLF rats.
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and the downregulation (-) is presented as the levels of
normal control divided by that of AFL. The results
demonstrated that CRP and Hp were dramatically up-
and downregulated, respectively (CRP: +4.71-fold; HP:
-11.54-fold, Table 2).
CRP and Hp validation
We were interested in characterizing the role of CRP
and Hp in AFL due to significant changes in their pro-
tein expressions. In the process of Western blotting, we
precisely controlled the loading protein to 20 μg, and
the total protein stained by SYPRO Ruby was used as a
Figure 1 Histological analysis and comparisons among four groups of rats. Images of livers from normal control, rats with alcoholic fatty
liver (AFL), non-alcoholic fatty liver (NAFL, fed 60% fructose) and liver fibrosis (left column) were analyzed by hematoxylin and eosin (H&E)
staining (right column). In AFL and NAFL rats, livers were filled with prominent fatty change. The scale bar represents 25 μm for normal, AFL and
NAFL; but 100 μm for liver fibrosis.
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show that CRP particularly increased in AFL rats com-
pared to all other groups including normal rats and rats
with NAFL disease or liver fibrosis (all p <0 . 0 5 ) ,
demonstrating that CRP is a putative biomarker of AFL.
Meanwhile, Hp did not significantly decrease in the
serum of AFL rats according to the Western blotting
analysis (Figure 4A). Interestingly, we observed that CRP
and Hp were both downregulated in the serum of liver
fibrosis rats compared to normal, AFL, and NAFL rats
(Figure 4B, C, all p < 0.05). On the other hand, we also
examined the level of alpha1 antitrypsin (AAT) to
exclude the elevation of CRP derived from ethanol-
induced gastrointestinal inflammation. The results
showed that AAT levels were not increased in
the serum of AFL rats compared to healthy controls
(Figure 4D).
Moreover, in order to evaluate the decreased expres-
s i o n so fC R Pa n dH pi nt h es e r u mo fl i v e rf i b r o s i sr a t s ,
we measured serum CRP and Hp concentrations in clin-
ical patients with non-alcoholic steatohepatitis (NASH)
and HCV-induced liver fibrosis compared to healthy
controls. Table 3 shows that CRP and Hp were lower in
patients with HCV-induced liver fibrosis, which was
consistent with the results demonstrated by Western
blotting, suggesting that CRP and Hp are reliable bio-
markers of liver fibrosis as downregulated proteins.
I n t e r e s t i n g l y ,w ef o u n dt h a ts e r u mH pw a se l e v a t e di n
NAFL rats, but lower in NASH patients, implying that
t h ee x p r e s s i o no fH pm a yv a r yb e t w e e nt h en o n -
necroinflammatory stage (NAFL) and necroinflamma-
tory stage (NASH).
Discussion
The aim of this study was to determine the putative sero-
logical biomarkers of AFL using 2D-DIGE, and then
these candidate markers were validated by Western blot-
ting. To characterize AFL disease markers, our experi-
mental strategy was first to induce patholophysiological
abnormalities in animals by administering alcohol, high
calories of compounds such as: fructose or fats, and
drinking water with TAA, a fibrosis-inducing chemical.
Under this experimental platform, rats should have
developed AFL, NAFL and liver fibrosis, allowing us to
determine the signature biomarkers for AFL, which is the
early stage in the alcohol-induced liver disease. From our
rodent models, we determined that CRP levels were sig-
nificantly elevated in the serum of rats with AFL, pre-
sumably as a reliable biomarker compared to that in
livers of healthy or sick rats with other liver diseases.
Indeed, CRP increases in other conditions, such as
inflammation, obesity [17,18], and cardiovascular disease
[19,20]; however, it is also a elevated AFL-induced pro-
tein in rats as discovered in this study. Here, our discov-
ery provides a hint that CRP can be used to distinguish
AFL from normal or otherwise diseased livers. A pre-
vious report indicated that CRP is a non-invasive marker
of alcoholic hepatitis in heavy drinkers compared to
Figure 2 Determination of serum biomarkers of alcoholic fatty liver (AFL) using 2D-DIGE. (A) The experimental design used two individual
samples each from healthy controls and AFL. (B) The combination of two different acquired images, in which, green color represents Cy3-labeled
normal control and red color represents Cy5-labeled AFL. (C) The identified proteins are indicated by arrows on the 2D gel. Ultimately there
were eight proteins selected according to statistical significance with a t-test value of < 0.05 (p < 0.05) as analyzed by the DeCyder software.
Vitamin D-binding protein (VDBP), haptoglobin (HP), C-reactive protein (CRP), alpha-fetoprotein (AFP), inter-alpha-inhibitor H4 heavy chain (ITIH4),
serine protease inhibitor Kazal-type 5 (SPINK5) and heak shock protein 75 kDa (HSP75) and afamin.
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Page 5 of 10Figure 3 Stereopictures and detailed images of eight putative biomarkers. VDBP, vitamin D binding protein; HP, haptoglobin; CRP, C-
reactive protein; AFP, alpha-fetoprotein; ITIH4, Inter-alpha-inhibitor H4 heavy chain; SPINK5, Serine protease inhibitor Kazal-type 5; HSP75, Heak
shock protein 75 kDa. The protein spots are indicated by arrows. Three proteins, CRP, AFP and afamin, were upregulated whereas the other
proteins, including Hp, ITIH4, APINK5, HSP75 and VDBP, were downregulated.
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Page 6 of 10hepatitis unrelated to alcohol [7]. In this study, we dis-
covered that CRP levels were elevated in AFL rats com-
pared to healthy animals, and rats with other forms of
liver diseases, such as NAFL and TAA-induced liver
fibrosis. Although the use of moderate alcohol con-
sumption can lower the level of CRP in the serum and
decrease cardiovascular mortality [21], in our study the
intake of high amounts of alcohol in this rodent model
increased the level of serum CRP, suggesting that the
intake of ethanol is positively associated with the level
of serum CRP. To our knowledge, CRP is considered an
inflammatory protein produced from macrophages in
the liver and adipocytes [22,23]. In order to exclude ele-
vated CRP derived from a response to gastrointestinal
inflammation because of ethanol consumption, we
examined protein levels of alpha1 antitrypsin, an acute-
phase marker [24,25], determined by Western blotting,
which provided a positive reference of an inflammatory
response. The results showed that levels of alpha1 anti-
trypsin in rats among the four groups were the same
(Figure 4A, D), indicating that the elevation of CRP was
not due to gastrointestinal inflammation. Moreover, in
vitro study revealed that ethanol can directly trigger the
secretion of CRP in HepG2 cells (data not shown).
Herein, the results suggest that ethanol-induced forma-
tion of fatty liver was strongly related to the induction
of serum CRP in rats supplied with excess ethanol.
An increase in CRP was also reported to be associated
with obesity [17,18]. To address our concern for the
obesity issue, we also measured animal weight in all
Table 2 Protein spots identified by MALDI-TOF/TOF MS
Gene name Protein name Mr (Da)/pI Coverage ratio Regulation
¶ p value
Crp C-reactive protein 25452/4.89 7%
§ +4.71 0.02
Afm Afamin 49311/6.14 59% +1.64 0.04
Afp Alpha-fetoprotein 47195/5.47 3%
§ +1.46 0.03
Hp Haptoglobin 39052/6.10 48% -11.54 0.04
Gc Vitamin D-binding protein 53493/5.65 4%
§ -1.74 0.04
Itih4 Inter-alpha-inhibitor H4 heavy chain 103885/6.08 48% -1.66 0.03
Spink5 Serine protease inhibitor Kazal-type 5 114816/8.68 74% -1.67 0.04
Trap1 Heak shock protein 75 kDa, mitochondrial 80639/6.56 57% -1.96 0.02
§Those proteins were identified by MS/MS.
¶ Presented as up- (+) or down regulation (-) compared to normal controls.
Figure 4 Evaluation of the expressions of alcoholic fatty liver (AFL) biomarkers using western blotting. (A) Confirmation of C-reactive
protein (CRP) and haptoglobin (Hp) expression by Western blotting. AAT was used as an indicator represented as a positive inflammatory
protein for gastrointestinal inflammation (B) The semi-quantification of the results of Western blotting. CRP increased in the serum of AFL rats
compared to normal, NAFL and liver fibrosis ones, but decreased in TAA-induced liver fibrosis. (C) Hp increased in rats suffering from NAFL, but
decreased in liver fibrosis compared to the controls. (D) AAT was not affected among the rats. Three individual samples of healthy controls,
NAFL, and liver fibrosis, and five samples of AFL were examined by using Western blotting. N, normal controls; AFL, alcoholic fatty liver; NAFL,
non-alcoholic fatty liver; CRP, C-reactive protein; Hp, haptoglobin; AAT, alph1 antitrypsin. *p < 0.05, compared to healthy controls;
#p < 0.05 as
compared to the other groups.
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ent in the liver tissues of rats fed diets containing a high
fructose content (HF-NAFL) which did not increase
serum CRP. In AFL rats, macrovesicular fat was also
observed, but serum CRP was elevated. Therefore, this
suggests that alcohol abuse may cause fatty liver and
induce high serum CRP levels, indicating that CRP may
be qualified as a unique biomarker of AFL.
Administration of ethanol can elicit oxidative stress
and injury to the liver [4,26], and the presence of poly-
unsaturated fats can induce the production of cyto-
chrome P4502E1 (CYP2E1) [27,28]. Under conditions of
persistent ethanol stimulation, CYP2E1 seems to play a
critical role in metabolizing and activating many toxico-
logical substances such as reactive oxygen species (ROS)
[26,29]. A recent study indicated that cytokines such as
tumor necrosis factor-alpha and interleukin-10 in adi-
pose tissues of acute alcoholic hepatitis patients were
elevated, and were correlated with the serum CRP con-
centration [30], implying that inflammation caused the
production of CRP. Although the mechanism of how
ethanol induces CRP in serum is unclear, in this study,
we discovered that ethanol consumption is an important
factor positively associated with the production of
serum CRP.
In addition to the increased CRP levels in AFL rats,
serum Hp was also discovered to be a biomarker of AFL
with reduced expression levels in the serum of AFL rats
using 2D-DIGE. However, Hp was elevated in the serum
of NAFL rats and even decreased in that of rats with
TAA-induced liver fibrosis (Figure 4C). Previous studies
reported by Chiellini’s group indicated that elevated
serum Hp is recognized as a marker of adiposity [31].
Our results demonstrate thatH pi sn o to n l yi n c r e a s e d
in NAFL, but also decreased in TAA-induced and HCV-
induced liver fibrosis. Furthermore, Shu et al. indicated
that Hp was overexpressed in hepatocellular carcinoma
compared to those with hepatitis B virus (HBV)-related
cirrhosis [32]. However another research group led by
Dr. Lee reported that Hp levels were decreased indepen-
dently in hepatic fibrosis in chronic liver disease [33].
Therefore, the level of serum Hp may vary under var-
ious pathophysiological situations or stages in clinical
liver diseases. Hp is also used in the panel of AshTest
[34] as a down-regulated protein. In this study, we
found that Hp was a downregulated protein in NASH
and HCV-infected liver fibrosis although we found that
H pm a yb eh i g h e ri nt h es e r u mo fN A F Lr a t s .T h e
results demonstrated that Hp is a reliable downregulated
biomarker of NASH and liver fibrosis in clinical cases.
Conclusions
For a diagnosis of alcoholic liver disease, a biopsy is the
gold standard. Current studies focusing on the discovery
of a noninvasive biomarker panel for diagnosis or prog-
nosis imply that development of a noninvasive method
is urgent. CRP is considered to be a marker of athero-
sclerotic cardiovascular disease in clinical analysis
[19,20], modulating endothelial function in the process
of atherogenesis [35]; therefore, we suggest that using
CRP to distinguish AFL from the other liver diseases
may consider the complication of cardiovascular disease.
In conclusion, this is the first report to reveal new can-
didate biomarkers of AFL using a proteomics analysis.
In this study, eight AFL-associated serological proteins
were disclosed, which may be associated with AFL in
rats. We suggest that CRP is suitable to serve as a can-
didate biomarker of AFL, and Hp is a reliable biomarker
that decrease in NASH and liver fibrosis. In particular,
serum CRP may be qualified to be an elevated surveil-
lance target for early diagnosis of AFL in clinical
screening.
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Table 3 Serum concentration of C reactive protein (CRP) and haptoglobin (Hp) in clinical patients
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Hp
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NASH (19) F1~F2
(19, 100%)
Stage 0~1
(7, 37%)
Stage 0~4
(18, 95%)
ND 0.74 ± 0.39*
Stage 2~3
(12, 63%)
Stage 5~13
(1, 5%)
HCV-
liver fibrosis (17)
F1~F2
(7, 41%)
Stage 0~1
(15, 88%)
Stage 0~4
(2, 12%)
1.31 ± 0.44* 0.45 ± 0.58*
,#
F3~F4
(10, 59%)
Stage 2~3
(2, 12%)
Stage 5~13
(15, 88%)
The fibrotic stage was determined according to the Metavir classification. The stage of p-steatosis was determined according to the fatty change. HAI,
necroinflammatory scores. NASH, non-alcoholic steatohepatitis; ND, not determined.* p < 0.05, compared to healthy controls.
# p < 0.05, compared to NASH. The
significance was calculated according to Student’s t-test. The data are presented as the mean ± SEM.
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